LPC Snapshot - April 2022
Exploring Manufacturing Options for Engineered T-cell Therapies
By:
Hannah W. Song, Ph.D
Biologist, Product Development
Center for Cellular Engineering, National Institute’s of Health
Bethesda, MD, USA
Steven L. Highfill, Ph.D.
Director, Product Development
Center for Cellular Engineering, National Institute’s of Health
Bethesda, MD, USA
There are a vast number of approaches to manufacture genetically modified T-cells for clinical purposes, with options ranging from mostly manual manipulations to entirely end-to-end automation. In this Snapshot, we explore some of the commonly-used approaches for distinct aspects of the culture process (including cell selection, expansion, transduction, and fill/finish) and layout some of the advantages and disadvantages of each approach. We hope this review will help guide cell therapy centers in selecting the most appropriate methods for their particular processes.
Read Article
#LabPractices
#29.3